Kenichi Saito

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.4K citations · Full text

Medicine, Oncology, Pharmacology +12

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu et al. · Journal of Clinical Oncology · 2020 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration.

Kenichi Saito, John S. Elce, James E. Hamos et al. · Proceedings of the National Academy of Sciences · 1993 · 582 citations

Life Sciences, Neurobiology, Neuroscience +17

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

Tatsuya Yamashita, Masatoshi Kudo, Kenji Ikeda et al. · Journal of Gastroenterology · 2019 · 227 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Effects of a novel free radical scavenger, MCl-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.

H Kawai, H. Nakai, Mayuko Suga et al. · PubMed · 1997 · 226 citations

Medicine, Neuroscience, Pharmacology +16